三联疗法联合双歧杆菌四联活菌片对幽门螺杆菌感染消化性溃疡的疗效观察

An observation of triple therapy and Bifidobacterium tetravaccine tablets (live)in Helicobacter pylori patientswith peptic ulcer

目的 分析幽门螺杆菌感染消化性溃疡患者采用双歧杆菌四联活菌片联合三联疗法治疗的效果。方法 选择泉州市洛江区妇幼保健院收治的80例幽门螺杆菌感染消化性溃疡患者为研究群体,研究时间为2020年7月—2021年11月。通过随机摸红蓝球方式将所有患者划分成常规组以及试验组,其中摸红球为常规组(40例),摸蓝球为试验组(40例),予以常规组患者三联疗法干预,予以试验组患者双歧杆菌四联活菌片联合三联疗法干预。对比2组患者治疗总有效率、症状缓解率、溃疡愈合率以及幽门螺杆菌根除率、用药前后血清生长抑素以及胃动素水平、不良反应发生率。结果 试验组与常规组患者治疗总有效率分别是95.00%、77.50%(P<0.05)。试验组与常规组患者症状缓解率依次是92.50%、72.50%,幽门螺杆菌根除率依次是87.50%、62.50%,差异均有统计学意义(P<0.05)。用药后试验组患者血清生长抑素水平低于常规组,胃动素水平高于常规组(P<0.05),并且同组组内患者用药后血清生长抑素水平均低于用药前,胃动素水平相较于用药前高(P<0.05)。在不良反应方面,发生率试验组患者为20.00%,而常规组是22.50%,差异无统计学意义(P>0.05)。结论 幽门螺杆菌感染消化性溃疡患者采用双歧杆菌四联活菌片联合三联疗法治疗,能够缓解临床症状,消除幽门螺杆菌,改善血清生长抑素以及胃动素水平,提升治疗效果,并且用药后不良反应少,可发挥良好的干预作用。

Objective To analyze the effects of Bifidobacterium tetravaccine tablets(live)and triple therapy in helicobacter pylori patients with peptic ulcer.Methods The 80 cases ofHelicobacter pylori infection with peptic ulcer disease admitted to the institute were selected as the study group,and the study was started in July 2020 and ended in November 2021.All patients were divided into conventional groups and experimental groups by randomly touching red and blue ball,among which red ball was the conventional group(40 cases)and blue ball was the experimental group(40 cases)in the conventional group,bifidobacterium and triple therapy in the experimental group.Total effective rate,symptom remission rate,ulcer healing rate,helicobacter pylori resection rate,serum somatostatin and gastric motility and adverse event rate were compared.Results The total effective rate in the test group and routine group was 95.00%and 77.50%(P<0.05).The symptom remission rate in the test group and routine group was 92.50%and 72.50%.Helicobacter pylori resection rate in the test group and routine group was 87.50%and 62.50%(P<0.05).Serum somatostatin levels were lower than conventional group,gastrodykinin levels were higher than conventional group,and the serum somatostatin level was lower than before administration,and higher than before administration(P<0.05).In terms of adverse reactions,the patients were 20.00%in the experimental group,compared with 22.50%in the conventional group,with no significant difference(P>0.05).Conclusion Bifidobacterium tetravaccine tablets(live)and triple therapy can reduce the clinical symptoms and helicobacter pylori,improve the serum somatostatin and gastric motility and treatment effects,produce less impact on the adverse drug reactions.